Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Total Current Liabilities for 13 consecutive years, with $19.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 10.98% to $19.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.9 million, a 10.98% increase, with the full-year FY2025 number at $19.9 million, up 10.98% from a year prior.
  • Total Current Liabilities was $19.9 million for Q4 2025 at Niagen Bioscience, down from $22.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $22.7 million in Q3 2025 to a low of $16.2 million in Q2 2021.
  • A 5-year average of $18.9 million and a median of $18.4 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: decreased 12.97% in 2024, then rose 28.32% in 2025.
  • Niagen Bioscience's Total Current Liabilities stood at $17.6 million in 2021, then increased by 1.45% to $17.9 million in 2022, then increased by 15.41% to $20.6 million in 2023, then fell by 12.97% to $17.9 million in 2024, then grew by 10.98% to $19.9 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Total Current Liabilities are $19.9 million (Q4 2025), $22.7 million (Q3 2025), and $22.3 million (Q2 2025).